Cancer name Head and Neck Squamous Cell Carcinoma
Cancer Type HNSC
Immunotherapy type Immune Checkpoint Therapy
Treatment Nivolumab
Drugstatus Approved
Drugbank ID DB09035(DB06132)
Checkpoints PD-1
Signature Type Protein
Signature PD-L1
Official Symbol CD274
Mode of action PROT_R_UP
Description for ‘mode of action’：the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation)，Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental NA
Description Since tumors expressing PD-L1 show the bestresponse to Nivolumab, it is important to understandthe proportion of HNSCC that express the PD-L1 ligand. Objective responses were only seen in those patients with tumors expressing PD-L1 (defined asexpression in >5% of cells). When considering only tumors express-ing PD-L1, there was an objective response in 36% of patients. This response rate is significant as it is seen in a population treated withnivolumab as monotherapy after failure of standard treatment reg-imens.
PMID 29094075
Title Genomics and advances towards precision medicine for head and neck squamous cell carcinoma